Navigation Links
ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
Date:1/6/2009

Program Expands on Successful Results from prior U.S., U.K. and China Trials

SAN DIEGO, Jan. 7 /PRNewswire/ -- Vital Therapies, Inc. (VTI), a development stage company targeting liver disease, today announced patient enrollment has begun for a randomized, controlled, multi-center, Phase 2 clinical trial that will study the Extracorporeal Liver Assist Device (ELAD) as a treatment for patients with Acute Liver Failure (ALF) under three protocols. The study is open for enrollment at seven U.S. sites, which will be expanded to 15 sites in the U.S. and Europe during the first half of 2009. Six patients have already been enrolled in the first protocol and four patients have been treated under the emergency use Expanded Access regulations.

This trial expands on prior results from phase 1 and 2 U.S. and U.K. trials and a pivotal, randomized, controlled clinical trial at two sites in China during 2006/2007. In that study, 69 patients with hepatitis B or C who had suffered ALF were treated with either ELAD or standard therapy. Thirty day transplant free survival rates were statistically significant in the ELAD group vs. concurrent controls. A marketing application was submitted to China's State Food and Drug Administration (SFDA) in September 2007 and is under review.

ALF afflicts more than 30,000 U.S. patients each year including people with chronic liver disease like hepatitis, or without chronic disease, such as individuals whose livers were harmed by taking too much acetaminophen pain medicine.

For ALF patients, liver transplantation is the only therapy proven to impact survival. However, it has a cost exceeding $350,000 and there is a worldwide shortage of livers for transplant. ELAD was designed to address both problems since it may support regeneration of a patient's native liver, or maintain sufficient liver function until a transplant organ is available.

VTI Chairman and CE
'/>"/>

SOURCE Vital Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
2. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
3. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
6. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
7. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
8. New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients
9. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
10. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
11. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye, today ... 2014 Medical Technology & Diagnostics Forum in ... on Thursday, November 20 at 12:30 p.m. PT/3:30 p.m. ... overview of the Company,s current business trends, financial results, ...
(Date:11/17/2014)... Calif. , Nov. 17, 2014 Asterias ... in the emerging field of regenerative medicine, today announced ... of Research and Development, will participate in a live ... Regenerative Medicine (CIRM) discussing the latest progress in stem ... The CIRM Google Hangout session is scheduled for Tuesday, ...
(Date:11/17/2014)... 17, 2014  CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... investor conferences. Jefferies 2014 Global Healthcare Conference ... EST, London, England . ... December 3 at 9:00 a.m. EST, New York, ... webcast live and available for replay after the presentation. The webcast ...
Breaking Medicine Technology:STAAR Surgical To Present At The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum 2Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury 2CTI BioPharma to Present at the Upcoming Investor Conferences 2
... Edge EHR Corp., EDGE, a provider of Dental ... to announce the release of edgeDMS™ for ... leverage the awesome power of the Apple® iPad. ... (Logo:   http://photos.prnewswire.com/prnh/20100310/AQ68604LOGO ) The ...
... Calif., Dec. 21, 2010 Jazz Pharmaceuticals, Inc. (Nasdaq: ... States Patent and Trademark Office (USPTO) has issued a ... "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for ... is also listed in the FDA,s Approved Drug Products ...
Cached Medicine Technology:Edge EHR Corp. Announces edgeDMS for iPad, Native Touch-Based Clinical Charting Software for the Paperless Dental Office. 2Jazz Pharmaceuticals Announces New Patent Issued for Sodium Oxybate 2
(Date:11/18/2014)... Cristcot Inc., a global life sciences ... specialized drug delivery systems, today announced that the ... for the technology, which encompasses the company’s commercially ... patent was awarded to the inventor Jennifer Davagian ... to Cristcot Inc. The patented technology, titled “Method ...
(Date:11/18/2014)... Medicationdiscountcard.com's blog offers health ... company's reputation for helping consumers save money at ... offer at http://blog.medicationdiscountcard.com/ . , Consumers need ... Affordable Care Act and the state health benefit ... about a variety of prescription drug and health ...
(Date:11/18/2014)... HealthDay Reporter MONDAY, Nov. 17, ... prove effective at lowering LDL ("bad") cholesterol levels for ... That,s the conclusion of a clinical trial presented ... Chicago. The drug, alirocumab, outperformed the on-the-market medication ... statins, Zetia, said lead researcher Dr. Patrick Moriarty, director ...
(Date:11/18/2014)... 2014 (HealthDay News) -- Women who started smoking at ... chronic, severe menstrual pain, a new study suggests. ... While smoking has been suspected as a risk factor ... the authors of the new study said. The ... a long-term study of women,s health in Australia. About ...
(Date:11/18/2014)... 18, 2014 Global Partnership ... the telehealth platform to bring quality healthcare to ... passion, GPT created Global Partnership for TeleHealth Missions ... existing telehealth network. GPTM focuses specifically on ... and disaster relief organizations. , Michael ...
Breaking Medicine News(10 mins):Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Medicationdiscountcard.com Building Virtual Library of Resources to Help Consumers Navigate Healthcare Landscape 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Global Partnership for TeleHealth (GPT) is Focused on Using the telehealth Platform to Bring Quality Healthcare to Populations in Need Worldwide 2
... a History of Eating Disorders More at Risk for ... for Eating and Anxiety Disorders ( www.remudaranch.com ), the ... new pressure to look perfect while pregnant. "With the ... an increased pressure to look perfect and thin during ...
... is the only authorized online learning program ... Known for bringing innovation to the chiropractic ... only web-based seminar program dedicated exclusively to ... Online, the online learning system authorized by ...
... 19 Abbott announced today,that the U.S. ... the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for ... analyzer. , Cartridges for E3+, ... patient,s,metabolic state within a few minutes. The glucose ...
... Amazing Heat Pack by Comfort Now, Inc., a revolutionary ... pain relief for athletes, arthritics, chronic pain sufferers, premenstrual ... musclesBURLINGTON, Ontario, Jan. 19 Not since the 1920 ... aid product been released as The Amazing Heat Pack, ...
... Commitment to Healthy and Successful Vascular Access for ... Vascular Access(SM), the nation,s leading provider of vascular ... of managed vascular access centers has collectively ,touched, ... Lifeline Vascular Access managed center Nephrology Vascular Lab ...
... The 2008 Frost & Sullivan Technology Innovation Award ... presented to TECNIMED srl for pioneering THERMOFOCUS, the first ... available with a new, rapid, room temperature stabilization system. ... the company that has demonstrated technological superiority within its ...
Cached Medicine News:Health News:Remuda Ranch Reports More Women Seek to Be Thin During Pregnancy 2Health News:Activator Methods Introduces Web-Based Seminar Program 2Health News:Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer 2Health News:Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer 3Health News:The Amazing Heat Pack: The Most Innovative First Aid Solution Since the Band-Aid 2Health News:Lifeline Vascular Access Treats a Quarter Million Patients 2Health News:Lifeline Vascular Access Treats a Quarter Million Patients 3Health News:TECNIMED Picks Up Frost & Sullivan Award for its Innovative THERMOFOCUS 2Health News:TECNIMED Picks Up Frost & Sullivan Award for its Innovative THERMOFOCUS 3Health News:TECNIMED Picks Up Frost & Sullivan Award for its Innovative THERMOFOCUS 4
... The Vitros 250 is ... meet requirements in multiple environments ... large hospitals, clinics and satellite ... features on-board dilution, and can ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Architect i2000 is a flexible solution for your evolving laboratory providing high throughput and walkaway time with built-in flexibility....
... The Bayer Immuno 1 provides ... immunoassay instrument with over 50 ... endocrinology, tumor marker, therapeutic drug, ... can be performed on a ...
Medicine Products: